News

Risk of Developing Certain Second Cancers May Vary According to non-Hodgkin Lymphoma Subtype

By

Susan Moench, PhD, PA-C

Publish Date July 19, 2019

A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.

Depressive Symptoms May Be Associated With Survival in Patients With Hematologic Malignancies

By

Lauren Dembeck, PhD

Publish Date July 19, 2019

Patients with newly diagnosed malignant lymphoma or multiple myeloma who reported depressive symptoms prior to the start of chemotherapy had poorer survival, researchers found.

Potential Early Drivers of Disease in Treatment-Naive CLL Identified

By

Christina Bennett, MS

Publish Date July 18, 2019

Mutated ATM and unmutated IGHV were identified as potential early drivers of disease in treatment-naive patients with chronic lymphocytic leukemia.

Phase 3 Study Evaluating Novel Therapy for Pancreatic Cancer Discontinued

By

Brian Park, PharmD

Publish Date July 17, 2019

Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.

TKI Dose Reduction Improves Treatment-Free Remission Protocols for Chronic Myeloid Leukemia

By

Susan Moench, PhD, PA-C

Publish Date July 17, 2019

Study sought to determine the effects of dose reductions in TKI therapy prior to complete cessation improves treatment-free remission in patients with CML.

Prostate Cancer ADT Raises Dementia Risk, Study Finds

By

Jody A. Charnow, Editor

Publish Date July 17, 2019

Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.

Risk Factors for CVD More Common in Postmenopausal Women Who Survived Breast Cancer

By

Hannah Dellabella

Publish Date July 16, 2019

Researchers compared the development of specific CVD risk factors in postmenopausal women who survived breast cancer and women without history of breast cancer.

Determining Risk Factors for Recurrence of Primary Localized Cutaneous Melanoma

By

Susan Moench, PhD, PA-C

Publish Date July 15, 2019

Researchers sought to determine the risk of disease recurrence in patients with localized melanoma at high risk of disease metastasis.

Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date July 12, 2019

In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.

Effective Communication as Essential Tool for Successful Patient Navigation

By

Susan Moench, PhD, PA-C

Publish Date July 12, 2019

The importance of interactions with patients, communication with the oncology care team, and involvement in navigation research are discussed in this oral presentation.

Incidence of Early-Onset Colon and Rectal Cancers Highest in Southern US States but Rising Fastest in Western US States

By

Susan Moench, PhD, PA-C

Publish Date July 12, 2019

The incidence of early onset colorectal cancer per 100,000 people increased from 6.7 during 1995-1996 to 11.5 during 2014-2015 for residents of the state of WA.

Comparing Long-Course Chemoradiation With Short-Course Radiation Therapy in Rectal Cancer

By

Susan Moench, PhD, PA-C

Publish Date July 12, 2019

Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.

Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication

By

Brian Park, PharmD

Publish Date July 11, 2019

The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.

Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma

By

Sonali Gattani

Publish Date July 11, 2019

Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.

Prostate Cancer Salvage Cryotherapy May Offer Durable Tumor Control

By

Jody A. Charnow, Editor

Publish Date July 10, 2019

In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.

Oncology Nurses Report Knowledge and Practice Gaps in Bone Health Management

By

Susan Moench, PhD, PA-C

Publish Date July 10, 2019

A survey study sought to identify confidence levels among oncology nurse specialists in managing bone health of patients with cancer, and barriers to care.

Flow Cytometry as a Relapse Risk Assessment Tool in T-Cell Acute Lymphoblastic Leukemia

By

Vicki Moore, PhD

Publish Date July 8, 2019

An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.

Efficacy of Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia

By

Marielle Fares, PharmD

Publish Date July 8, 2019

The majority of patients achieved complete remission with or without incomplete count recovery after receiving 12 cycles of combination therapy.

Machine Versus Physician: Assigning Diagnoses to Pigmented Skin Lesions

By

Susan Moench, PhD, PA-C

Publish Date July 5, 2019

Approximately one half of all biopsied/excised lesions from patients who have sun-damaged skin are nonmelanocytic.

Cytoreductive Nephrectomy Alone for mRCC Linked to Better Survival

By

Jody A. Charnow, Editor

Publish Date July 5, 2019

Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.